A Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of VIS954 in Healthy Adult Participants

A Phase 1, Randomized, Placebo-controlled, Double Blind, Single Ascending Dose, First-in-human Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of VIS954 in Healthy Male and Female Participants

Status

Completed

Phases

Phase 1

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT06212804

Enrollment

Registered

2024-01-19

Start date

2023-11-21

Completion date

2024-07-19

Last updated

2026-04-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy Volunteers

Brief summary

This is a first-in-human (FIH), randomized, placebo-controlled, double-blind, single ascending dose (SAD) study to assess the safety and tolerability of VIS954, a monoclonal antibody, in healthy adult male and female participants.

Detailed description

The study will be conducted in 6 sequential cohorts. Each cohort will enroll 9 participants, randomized to VIS954 or placebo at a ratio of 7:2. On Day 1, a single dose of VIS954 or placebo will be administered SC. Sentinel participants will be utilized in each cohort. After 14 days, the safety data will be evaluated and a decision to admit and dose the next cohort will be made. The total duration of the clinical study per participant will be up to 102 days (approximately 4 months).

Interventions

BIOLOGICALVIS954

A humanized IgG4 monoclonal antibody.

OTHERPlacebo

VIS954 Placebo

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Intervention model description

Phase 1, randomized, placebo-controlled, double-blind, single ascending dose study

Eligibility

Sex/Gender

ALL

Age

18 Years to 55 Years

Healthy volunteers

Yes

Inclusion criteria

1. Male or female participant between 18 to 55 years of age, inclusive, at the screening visit. 2. Non-Japanese participant: Participant does not meet the criteria specified below for 'Japanese Participant'. 3. Japanese participant: Participant is of Japanese descent as evidenced by verbal confirmation of familial heritage (a participant's 4 grandparents were born in Japan and recognized to be 'Japanese'). 4. Body mass index between 18.0 and 30.0 kg/m2, inclusive, at the screening visit. 5. Total body weight between 50.0 and 120.0 kg, inclusive, at the screening visit. 6. Capable of giving signed informed consent, which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and the protocol. 7. Willing and able to participate in the study for the defined duration of the study. 8. Female participants will be nonpregnant, nonlactating, and either postmenopausal for at least 1 year or surgically sterile for at least 3 months, or will agree to use highly effective methods of contraception from the period prior to study enrollment until 30 days after Day 56; women of childbearing potential must have a negative serum beta-human chorionic gonadotropin (β-hCG) test at screening and a negative urine pregnancy test at baseline prior to administration of the study intervention. 9. Male participants with female partners of childbearing potential must agree to use double barrier contraception or abstain from sex during the study and until 90 days after Day 56. Male participants must agree to refrain from sperm donation for the duration of the study and until 90 days after Day 56. This criterion may be waived for male participants who have had a vasectomy greater than 6 months prior to enrollment. 10. Healthy, as determined by prestudy medical evaluation (medical history, physical examination, vital signs, 12-lead ECG, and clinical laboratory evaluations), as judged by the principal investigator.

Exclusion criteria

1. Participant has a history or current evidence of a serious and/or unstable cardiovascular, respiratory, gastrointestinal, hematologic, autoimmune, blood dyscrasias or other medical disorder, including psychiatric disorders, cirrhosis, or malignancy. History of minor skin cancers (not including melanoma) or surgically treated, limited cervical carcinomas (ie, carcinoma in situ) are not exclusionary. 2. Participant is participating in another clinical study of any investigational drug, device, or intervention or has received any investigational medication during the last 30 days or 5 half-lives, whichever is longer, before baseline (Day -1). 3. Previous receipt of antibody or biologic therapy. 4. History of a previous hypersensitivity or severe allergic reaction with generalized urticaria, angioedema, or anaphylaxis to any of the ingredients of the VIS954 SC injection formulation. 5. Blood pressure \> 160/100 mmHg or \< 90/50 mmHg (may be repeated once if abnormal), at the screening visit or Day -1. 6. History of any infection requiring hospitalization or treatment with antivirals, antibiotics, or systemic antifungals within 3 months prior to screening. 7. Received a vaccination, other than COVID-19 vaccination, during the 30 days prior to administration of the first dose of study intervention. A COVID-19 vaccination cannot be received within 7 days prior to the first dose of study intervention and until 14 days after the last dose. 8. Has received any prescription or nonprescription (over-the-counter) medication during the last 30 days or 5 half-lives, whichever is longer, preceding baseline (Day -1), with the exception of acetaminophen, ibuprofen, naproxen (or other over-the-counter nonsteroidal anti-inflammatory drugs \[NSAID\]), hormonal contraceptives, topical medications, vitamins, and dietary or herbal remedies. 9. Any participant who has a recent history of alcohol or drug/chemical abuse, at the discretion of the investigator, will be excluded. 10. Enrolled participants must abstain from consumption of nicotine containing products from Day -1 through discharge. 11. Enrolled participants must abstain from consumption of cannabinoids from Day-1 through end of study. 12. For the duration of the study, enrolled male participants should not consume more than 15 standard drinks per week (7 days) and female participants should not consume more than 10 standard drinks per week (7 days). A standard drink equals 10 g of alcohol. Enrolled participants must abstain from consuming alcohol 48 hours prior to check-in on Day -1 through discharge. 13. Participant with a positive urine drug or alcohol breath screen test result at screening or Day -1. The urine drug screen and alcohol breath screen may be repeated once at the discretion of the investigator. The urine drug screen also screens for methylenedioxymethamphetamine and propoxyphene. If a participant tests positive on these tests, inclusion of that participant into the study will be based on the principal investigator's judgment with consultation, as needed, with the medical monitor and the sponsor. 14. Any chronic infectious disease (eg, chronic urinary tract infection, chronic sinusitis, bronchiectasis, active pulmonary or systemic tuberculosis \[TB\], chronic viral hepatitis such as hepatitis C or hepatitis B, or human immunodeficiency virus \[HIV\] infection). 15. Participant who has donated \> 500 mL of blood within 60 days prior to start of the screening visit or the participant has donated any plasma within 7 days prior to baseline (Day -1). 16. Coronavirus disease 2019: * Current symptoms of infection. * Diagnosis of COVID-19 (reverse transcription polymerase chain reaction \[RT-PCR\], antigen testing, or clinical diagnosis) in the 21 days prior to screening. * Ongoing diagnosis of "Long-COVID" symptoms, due to a prior COVID-19 infection. 17. Is an employee of the clinical research team (any sponsor or research site employee), or has a family member who is an employee of these organizations. 18. Participant is judged by the investigator or the medical monitor to be inappropriate for the study.

Design outcomes

Primary

Measure	Time frame	Description
Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Treatment-Emergent Serious Adverse Events (TESAEs)	From study intervention administration (Day 1) up to end of follow-up (Day 71)	An adverse event (AE) was any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. A serious adverse event (SAE) was any untoward medical occurrence that, at any dose, resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect, was a suspected transmission of any infectious agent via an authorized medicinal product or was an important medical event that jeopardized the participant or required medical or surgical intervention to prevent 1 of the other outcomes listed above. TEAEs were AEs that first occurred or worsened in severity after the study intervention administration, and up to Day 71 (including the follow-up period) after the study intervention administration.
Wong-Baker FACES Pain Rating Scale	Day 1 (1 and 4 hours post-dose), Day 2 (24 hours post-dose), and on Days 3 and 29	The Wong-Baker FACES Pain Rating Scale was a subjective self-report that was used to record each participant's perception of pain associated with their injection. The scale ranged from 0 to 10 and showed a series of faces ranging from a happy face at 0 which represented "no hurt" to a crying face at 10 which represented "hurts worst." Based on the faces and descriptions, the participant recorded their level of pain. Higher scores indicated more severe pain.

Secondary

Measure	Time frame	Description
Maximum Serum Concentration (Cmax) of VIS954	Day 1 (within 2 hours pre-dose) and at multiple timepoints post-dose up to Day 71	Blood samples were collected for measurement of serum concentrations of VIS954 at the specified time points from Day 1 (within 2 hours pre-dose) to Day 71. The pharmacokinetic (PK) parameters of VIS954 were derived using noncompartmental analysis method.
Time of Maximum Serum Concentration (Tmax) of VIS954	Day 1 (within 2 hours pre-dose) and at multiple timepoints post-dose up to Day 71	Blood samples were collected for measurement of serum concentrations of VIS954 at the specified time points from Day 1 (within 2 hours pre-dose) to Day 71. The PK parameters of VIS954 were derived using noncompartmental analysis method.
Area Under the Concentration-Time Curve From Pre-dose Extrapolated to Infinite Time (AUC0-inf) of VIS954	Day 1 (within 2 hours pre-dose) and at multiple timepoints post-dose up to Day 71	Blood samples were collected for measurement of serum concentrations of VIS954 at the specified time points from Day 1 (within 2 hours pre-dose) to Day 71. The PK parameters of VIS954 were derived using noncompartmental analysis method.
Area Under the Concentration-Time Curve From Pre-dose to the Last Quantifiable Concentration (AUC0-last) of VIS954	Day 1 (within 2 hours pre-dose) and at multiple timepoints post-dose up to Day 71	Blood samples were collected for measurement of serum concentrations of VIS954 at the specified time points from Day 1 (within 2 hours pre-dose) to Day 71. The PK parameters of VIS954 were derived using noncompartmental analysis method.
Apparent Terminal Elimination Half-Life (t1/2) of VIS954	Day 1 (within 2 hours pre-dose) and at multiple timepoints post-dose up to Day 71	Blood samples were collected for measurement of serum concentrations of VIS954 at the specified time points from Day 1 (within 2 hours pre-dose) to Day 71. The PK parameters of VIS954 were derived using noncompartmental analysis method.
Apparent Volume of Distribution (Vd/F) of VIS954	Day 1 (within 2 hours pre-dose) and at multiple timepoints post-dose up to Day 71	Blood samples were collected for measurement of serum concentrations of VIS954 at the specified time points from Day 1 (within 2 hours pre-dose) to Day 71. The PK parameters of VIS954 were derived using noncompartmental analysis method.
Apparent Clearance After Extravascular Dosing (CL/F) of VIS954	Day 1 (within 2 hours pre-dose) and at multiple timepoints post-dose up to Day 71	Blood samples were collected for measurement of serum concentrations of VIS954 at the specified time points from Day 1 (within 2 hours pre-dose) to Day 71. The PK parameters of VIS954 were derived using noncompartmental analysis method.
Time Spent Above 40 Percentage Receptor Occupancy (RO) for Neutrophils	Baseline (Day -1) up to Day 71	Blood samples were collected at the specified time points to characterize the effect of VIS954 binding. The time spent above 40% RO was defined as duration in hours from date and time of dosing until the date and time of pharmacodynamic (PD) collection when %RO \>40%. Baseline was defined as the last non-missing measurement taken prior to reference start date (including unscheduled assessments).

Countries

United States

Participant flow

Recruitment details

This Phase 1, double-blind, single ascending dose, first-in-human study was conducted in healthy participants at a single investigational site.

Pre-assignment details

The study was conducted in 6 sequential cohorts. In each cohort, participants were randomized in a 7:2 ratio to receive VIS954 or matching placebo. The study consisted of a screening period (up to 28 days before dosing), dosing on Day 1, a post-dose period (Days 5 to 57) and a final follow-up visit on Day 71. A total of 54 participants were enrolled in the study.

Participants by arm

Arm	Count
Cohort 1: VIS954 Dose 1 Participants received a single dose of VIS954 at Dose 1 via SC injection on Day 1.	7
Cohort 2: VIS954 Dose 2 Participants received a single dose of VIS954 at Dose 2 via SC injection on Day 1.	7
Cohort 3: VIS954 Dose 3 Participants received a single dose of VIS954 at Dose 3 via SC injection on Day 1.	7
Cohort 4: VIS954 Dose 4 Participants received a single dose of VIS954 at Dose 4 via SC injection on Day 1.	7
Cohort 5: VIS954 Dose 5 Participants received a single dose of VIS954 at Dose 5 via SC injection on Day 1.	7
Cohort 6: VIS954 Dose 6 Participants received a single dose of VIS954 at Dose 6 via SC injection on Day 1.	7
Cohort 1 to 6: Pooled Placebo Participants received a single dose of placebo matched to VIS954 via SC injection on Day 1.	12
Total	54

Baseline characteristics

Characteristic	Cohort 1: VIS954 Dose 1	Total	Cohort 1 to 6: Pooled Placebo	Cohort 6: VIS954 Dose 6	Cohort 5: VIS954 Dose 5	Cohort 4: VIS954 Dose 4	Cohort 3: VIS954 Dose 3	Cohort 2: VIS954 Dose 2
Age, Continuous	35.4 years STANDARD_DEVIATION 8.2	38.2 years STANDARD_DEVIATION 8.3	36.5 years STANDARD_DEVIATION 7.6	39.0 years STANDARD_DEVIATION 10.2	39.4 years STANDARD_DEVIATION 9.3	39.0 years STANDARD_DEVIATION 7.7	38.9 years STANDARD_DEVIATION 9.6	40.6 years STANDARD_DEVIATION 8.1
Ethnicity (NIH/OMB) Hispanic or Latino	1 Participants	10 Participants	3 Participants	2 Participants	1 Participants	2 Participants	0 Participants	1 Participants
Ethnicity (NIH/OMB) Not Hispanic or Latino	6 Participants	44 Participants	9 Participants	5 Participants	6 Participants	5 Participants	7 Participants	6 Participants
Ethnicity (NIH/OMB) Unknown or Not Reported	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants	0 Participants
Race/Ethnicity, Customized Asian	4 Participants	23 Participants	1 Participants	3 Participants	6 Participants	4 Participants	2 Participants	3 Participants
Race/Ethnicity, Customized Black	1 Participants	11 Participants	4 Participants	0 Participants	0 Participants	1 Participants	2 Participants	3 Participants
Race/Ethnicity, Customized Multiple	0 Participants	4 Participants	1 Participants	1 Participants	0 Participants	0 Participants	2 Participants	0 Participants
Race/Ethnicity, Customized Other	0 Participants	2 Participants	1 Participants	0 Participants	0 Participants	1 Participants	0 Participants	0 Participants
Race/Ethnicity, Customized White	2 Participants	14 Participants	5 Participants	3 Participants	1 Participants	1 Participants	1 Participants	1 Participants
Sex: Female, Male Female	5 Participants	29 Participants	7 Participants	3 Participants	2 Participants	4 Participants	4 Participants	4 Participants
Sex: Female, Male Male	2 Participants	25 Participants	5 Participants	4 Participants	5 Participants	3 Participants	3 Participants	3 Participants

Adverse events

Event type	EG000 affected / at risk	EG001 affected / at risk	EG002 affected / at risk	EG003 affected / at risk	EG004 affected / at risk	EG005 affected / at risk	EG006 affected / at risk
deaths Total, all-cause mortality	0 / 7	0 / 7	0 / 7	0 / 7	0 / 7	0 / 7	0 / 12
other Total, other adverse events	2 / 7	1 / 7	1 / 7	1 / 7	3 / 7	2 / 7	4 / 12
serious Total, serious adverse events	0 / 7	0 / 7	0 / 7	0 / 7	0 / 7	0 / 7	0 / 12

Outcome results

Primary

Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Treatment-Emergent Serious Adverse Events (TESAEs)

An adverse event (AE) was any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. A serious adverse event (SAE) was any untoward medical occurrence that, at any dose, resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect, was a suspected transmission of any infectious agent via an authorized medicinal product or was an important medical event that jeopardized the participant or required medical or surgical intervention to prevent 1 of the other outcomes listed above. TEAEs were AEs that first occurred or worsened in severity after the study intervention administration, and up to Day 71 (including the follow-up period) after the study intervention administration.

Time frame: From study intervention administration (Day 1) up to end of follow-up (Day 71)

Population: The safety analysis set included all participants who received trial intervention (active or placebo).

Arm	Measure	Group	Value (COUNT_OF_PARTICIPANTS)
Cohort 1: VIS954 Dose 1	Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Treatment-Emergent Serious Adverse Events (TESAEs)	TEAEs	2 Participants
Cohort 1: VIS954 Dose 1	Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Treatment-Emergent Serious Adverse Events (TESAEs)	TESAEs	0 Participants
Cohort 2: VIS954 Dose 2	Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Treatment-Emergent Serious Adverse Events (TESAEs)	TEAEs	1 Participants
Cohort 2: VIS954 Dose 2	Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Treatment-Emergent Serious Adverse Events (TESAEs)	TESAEs	0 Participants
Cohort 3: VIS954 Dose 3	Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Treatment-Emergent Serious Adverse Events (TESAEs)	TEAEs	1 Participants
Cohort 3: VIS954 Dose 3	Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Treatment-Emergent Serious Adverse Events (TESAEs)	TESAEs	0 Participants
Cohort 4: VIS954 Dose 4	Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Treatment-Emergent Serious Adverse Events (TESAEs)	TEAEs	1 Participants
Cohort 4: VIS954 Dose 4	Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Treatment-Emergent Serious Adverse Events (TESAEs)	TESAEs	0 Participants
Cohort 5: VIS954 Dose 5	Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Treatment-Emergent Serious Adverse Events (TESAEs)	TEAEs	3 Participants
Cohort 5: VIS954 Dose 5	Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Treatment-Emergent Serious Adverse Events (TESAEs)	TESAEs	0 Participants
Cohort 6: VIS954 Dose 6	Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Treatment-Emergent Serious Adverse Events (TESAEs)	TEAEs	2 Participants
Cohort 6: VIS954 Dose 6	Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Treatment-Emergent Serious Adverse Events (TESAEs)	TESAEs	0 Participants
Cohort 1 to 6: Pooled Placebo	Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Treatment-Emergent Serious Adverse Events (TESAEs)	TEAEs	4 Participants
Cohort 1 to 6: Pooled Placebo	Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Treatment-Emergent Serious Adverse Events (TESAEs)	TESAEs	0 Participants

Primary

Wong-Baker FACES Pain Rating Scale

The Wong-Baker FACES Pain Rating Scale was a subjective self-report that was used to record each participant's perception of pain associated with their injection. The scale ranged from 0 to 10 and showed a series of faces ranging from a happy face at 0 which represented no hurt to a crying face at 10 which represented hurts worst. Based on the faces and descriptions, the participant recorded their level of pain. Higher scores indicated more severe pain.

Time frame: Day 1 (1 and 4 hours post-dose), Day 2 (24 hours post-dose), and on Days 3 and 29

Population: The safety analysis set included all participants who received trial intervention (active or placebo).

Arm	Measure	Group	Value (MEAN)	Dispersion
Cohort 1: VIS954 Dose 1	Wong-Baker FACES Pain Rating Scale	Day 2: 24 hours post-dose	0 units on a scale	Standard Deviation 0
Cohort 1: VIS954 Dose 1	Wong-Baker FACES Pain Rating Scale	Day 1: 1 hour post-dose	0 units on a scale	Standard Deviation 0
Cohort 1: VIS954 Dose 1	Wong-Baker FACES Pain Rating Scale	Day 29	0 units on a scale	Standard Deviation 0
Cohort 1: VIS954 Dose 1	Wong-Baker FACES Pain Rating Scale	Day 1: 4 hours post-dose	0 units on a scale	Standard Deviation 0
Cohort 1: VIS954 Dose 1	Wong-Baker FACES Pain Rating Scale	Day 3	0 units on a scale	Standard Deviation 0
Cohort 2: VIS954 Dose 2	Wong-Baker FACES Pain Rating Scale	Day 2: 24 hours post-dose	0 units on a scale	Standard Deviation 0
Cohort 2: VIS954 Dose 2	Wong-Baker FACES Pain Rating Scale	Day 1: 4 hours post-dose	0 units on a scale	Standard Deviation 0
Cohort 2: VIS954 Dose 2	Wong-Baker FACES Pain Rating Scale	Day 3	0 units on a scale	Standard Deviation 0
Cohort 2: VIS954 Dose 2	Wong-Baker FACES Pain Rating Scale	Day 1: 1 hour post-dose	0 units on a scale	Standard Deviation 0
Cohort 2: VIS954 Dose 2	Wong-Baker FACES Pain Rating Scale	Day 29	0 units on a scale	Standard Deviation 0
Cohort 3: VIS954 Dose 3	Wong-Baker FACES Pain Rating Scale	Day 29	0 units on a scale	Standard Deviation 0
Cohort 3: VIS954 Dose 3	Wong-Baker FACES Pain Rating Scale	Day 1: 4 hours post-dose	0 units on a scale	Standard Deviation 0
Cohort 3: VIS954 Dose 3	Wong-Baker FACES Pain Rating Scale	Day 1: 1 hour post-dose	0 units on a scale	Standard Deviation 0
Cohort 3: VIS954 Dose 3	Wong-Baker FACES Pain Rating Scale	Day 2: 24 hours post-dose	0 units on a scale	Standard Deviation 0
Cohort 3: VIS954 Dose 3	Wong-Baker FACES Pain Rating Scale	Day 3	0 units on a scale	Standard Deviation 0
Cohort 4: VIS954 Dose 4	Wong-Baker FACES Pain Rating Scale	Day 2: 24 hours post-dose	0 units on a scale	Standard Deviation 0
Cohort 4: VIS954 Dose 4	Wong-Baker FACES Pain Rating Scale	Day 1: 1 hour post-dose	0.3 units on a scale	Standard Deviation 0.8
Cohort 4: VIS954 Dose 4	Wong-Baker FACES Pain Rating Scale	Day 1: 4 hours post-dose	0 units on a scale	Standard Deviation 0
Cohort 4: VIS954 Dose 4	Wong-Baker FACES Pain Rating Scale	Day 3	0 units on a scale	Standard Deviation 0
Cohort 4: VIS954 Dose 4	Wong-Baker FACES Pain Rating Scale	Day 29	0 units on a scale	Standard Deviation 0
Cohort 5: VIS954 Dose 5	Wong-Baker FACES Pain Rating Scale	Day 1: 1 hour post-dose	0 units on a scale	Standard Deviation 0
Cohort 5: VIS954 Dose 5	Wong-Baker FACES Pain Rating Scale	Day 29	0 units on a scale	Standard Deviation 0
Cohort 5: VIS954 Dose 5	Wong-Baker FACES Pain Rating Scale	Day 2: 24 hours post-dose	0 units on a scale	Standard Deviation 0
Cohort 5: VIS954 Dose 5	Wong-Baker FACES Pain Rating Scale	Day 3	0 units on a scale	Standard Deviation 0
Cohort 5: VIS954 Dose 5	Wong-Baker FACES Pain Rating Scale	Day 1: 4 hours post-dose	0 units on a scale	Standard Deviation 0
Cohort 6: VIS954 Dose 6	Wong-Baker FACES Pain Rating Scale	Day 1: 1 hour post-dose	0 units on a scale	Standard Deviation 0
Cohort 6: VIS954 Dose 6	Wong-Baker FACES Pain Rating Scale	Day 29	0 units on a scale	Standard Deviation 0
Cohort 6: VIS954 Dose 6	Wong-Baker FACES Pain Rating Scale	Day 3	0 units on a scale	Standard Deviation 0
Cohort 6: VIS954 Dose 6	Wong-Baker FACES Pain Rating Scale	Day 1: 4 hours post-dose	0 units on a scale	Standard Deviation 0
Cohort 6: VIS954 Dose 6	Wong-Baker FACES Pain Rating Scale	Day 2: 24 hours post-dose	0 units on a scale	Standard Deviation 0
Cohort 1 to 6: Pooled Placebo	Wong-Baker FACES Pain Rating Scale	Day 3	0 units on a scale	Standard Deviation 0
Cohort 1 to 6: Pooled Placebo	Wong-Baker FACES Pain Rating Scale	Day 1: 4 hours post-dose	0.3 units on a scale	Standard Deviation 1.2
Cohort 1 to 6: Pooled Placebo	Wong-Baker FACES Pain Rating Scale	Day 2: 24 hours post-dose	0 units on a scale	Standard Deviation 0
Cohort 1 to 6: Pooled Placebo	Wong-Baker FACES Pain Rating Scale	Day 1: 1 hour post-dose	0.3 units on a scale	Standard Deviation 1.2
Cohort 1 to 6: Pooled Placebo	Wong-Baker FACES Pain Rating Scale	Day 29	0 units on a scale	Standard Deviation 0

Secondary

Apparent Clearance After Extravascular Dosing (CL/F) of VIS954

Blood samples were collected for measurement of serum concentrations of VIS954 at the specified time points from Day 1 (within 2 hours pre-dose) to Day 71. The PK parameters of VIS954 were derived using noncompartmental analysis method.